samedan logo
 
 
 
spacer
home > ebr > spring 2017 > pinpointing the problem
PUBLICATIONS
European Biopharmaceutical Review

Pinpointing the Problem

EBR: Biomarkers are fast becoming an essential part of drug discovery and development. How did we get here and what advantages do they bring?

Dr Mario L Rocci Jr: A biomarker is a tool we use to assess a bodily process or function. This can define what is abnormal or characteristic when a disease is present, and how this improves after the disease is ameliorated through some form of therapeutic treatment. For instance, biomarkers can involve the measurement of a specific substance in a blood, urine or tissue sample, or might be scans resulting from imaging evaluations.

So there are several ways that they can best be used in drug discovery and development. Efficacy biomarkers can be utilised as an indicator of whether a drug being manufactured is likely to be efficacious in improving disease. Good examples include the use of serum glucose measurements or the ability to reduce HbA1C levels when developing drugs to treat diabetes, and the use of serum cholesterol and low-density lipoprotein levels when creating therapies for atherosclerotic disease.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Mario L Rocci Jr, a Senior Vice President at ICON Laboratories, has authored over 150 publications including a book on regulated bioanalysis due out in 2017. He is a past president of the American Society for Clinical Pharmacology and Therapeutics and the American Association of Pharmaceutical Scientists (AAPS), where he received the AAPS Distinguished Service Award. Mario is a member of an External Advisory Board at the University of Kentucky, US, a fellow of the American College of Clinical Pharmacology, US, and a fellow and past Board member of the International Pharmaceutical Federation.
spacer
Dr Mario L Rocci Jr
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

X-Chem Acquires ComInnex

WALTHAM, Mass.; Oct. 25, 2021 (Business Wire) X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
More info >>

White Papers

The Emerging Use of Social Media in Orphan Disease Drug Research

Worldwide Clinical Trials Ltd

The use of various social media platforms, such as Twitter, Instagram, Facebook, and LinkedIn, for dissemination of clinical trial information has created a cornucopia of possibilities enabling clinical trial performance. Characterized by a people-to-people immediacy, social media permits extraordinarily adaptive modification of study information in real-time, and it does so in a highly targeted fashion.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement